• Citer

Riociguat in patients with chronic thromboembolic pulmonary hypertension: Results from an early access study

par McLaughlin, Vallerie;Pulido, Tomás;Pepke-Zaba, Joanna;Barberà, Joan Albert;Hoeper, Marius M.;Vachiery, Jean-Luc ;Lang, Istvan;Carvalho, Francine;Meier, Christian;Mueller, Katharina;Nikkho, Sylvia;Jansa, Pavel;D'Armini, Andrea Maria Aria A.M.;Nielsen-Kudsk, Jens Erik;Halank, Michael;Simonneau, Gerald;Grünig, Ekkehard;Ulrich, Silvia;Rosenkranz, Stephan;Gomez Sanchez, Miguel Angel
Référence BMC pulmonary medicine, 17, 1, 216
Publication Publié, 2017-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Background: Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical practice, as well as to provide patients with early access to riociguat before launch. Riociguat is approved for the treatment of inoperable and persistent/recurrent CTEPH. Methods: We performed an open-label, uncontrolled, single-arm, early access study in which 300 adult patients with inoperable or persistent/recurrent CTEPH received riociguat adjusted from 1 mg three times daily (tid) to a maximum of 2.5 mg tid. Patients switching from unsatisfactory prior pulmonary arterial hypertension (PAH)-targeted therapy (n=84) underwent a washout period of at least 3 days before initiating riociguat. The primary aim was to assess the safety and tolerability of riociguat, with World Health Organization functional class and 6-min walking distance (6MWD) as exploratory efficacy endpoints. Results: In total, 262 patients (87%) completed study treatment and entered the safety follow-up (median treatment duration 47 weeks). Adverse events were reported in 273 patients (91%). The most frequently reported serious adverse events were syncope (6%), right ventricular failure (3%), and pneumonia (2%). There were five deaths, none of which was considered related to study medication. The safety and tolerability of riociguat was similar in patients switched from other PAH-targeted therapies and those who were treatment naïve. In patients with data available, mean±standard deviation 6MWD had increased by 33±42 m at Week 12 with no clinically relevant differences between the switched and treatment-naïve subgroups. Conclusions: Riociguat was well tolerated in patients with CTEPH who were treatment naïve, and in those who were switched from other PAH-targeted therapies. No new safety signals were observed. Trial registration: ClinicalTrials.org NCT01784562. Registered February 4, 2013.